PMID- 14966352
OWN - NLM
STAT- MEDLINE
DCOM- 20041005
LR  - 20181113
IS  - 1011-8934 (Print)
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Linking)
VI  - 19
IP  - 1
DP  - 2004 Feb
TI  - Continuous brain-derived neurotrophic factor (BDNF) infusion after 
      methylprednisolone treatment in severe spinal cord injury.
PG  - 113-22
AB  - Although methylprednisolone (MP) is the standard of care in acute spinal cord 
      injury (SCI), its functional outcome varies in clinical situation. Recent report 
      demonstrated that MP depresses the expression of growth-promoting neurotrophic 
      factors after acute SCI. The present study was designed to investigate whether 
      continuous infusion of brain-derived neurotrophic factor (BDNF) after MP 
      treatment promotes functional recovery in severe SCI. Contusion injury was 
      produced at the T10 vertebral level of the spinal cord in adult rats. The rats 
      received MP intravenously immediately after the injury and BDNF was infused 
      intrathecally using an osmotic mini-pump for six weeks. Immunohistochemical 
      methods were used to detect ED-1, Growth associated protein-43 (GAP-43), 
      neurofilament (NF), and choline acethyl transferase (ChAT) levels. BDNF did not 
      alter the effect of MP on hematogenous inflammatory cellular infiltration. MP 
      treatment with BDNF infusion resulted in greater axonal survival and regeneration 
      compared to MP treatment alone, as indicated by increases in NF and GAP-43 gene 
      expression. Adjunctive BDNF infusion resulted in better locomotor test scores 
      using the Basso-Beattie-Bresnahan (BBB) test. This study demonstrated that 
      continuous infusion of BDNF after initial MP treatment improved functional 
      recovery after severe spinal cord injury without dampening the acute effect of 
      MP.
FAU - Kim, Daniel H
AU  - Kim DH
AD  - Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 
      USA. spine@snuh.org
FAU - Jahng, Tae-Ahn
AU  - Jahng TA
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (GAP-43 Protein)
RN  - EC 2.3.1.6 (Choline O-Acetyltransferase)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Axons/pathology
MH  - Brain-Derived Neurotrophic Factor/metabolism/*pharmacology
MH  - Choline O-Acetyltransferase/metabolism
MH  - Female
MH  - GAP-43 Protein/metabolism
MH  - Gene Expression Regulation
MH  - Immunohistochemistry
MH  - Methylprednisolone/metabolism/*pharmacology
MH  - Osmosis
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Spinal Cord/pathology
MH  - Spinal Cord Injuries/*pathology
MH  - Time Factors
PMC - PMC2822246
EDAT- 2004/02/18 05:00
MHDA- 2004/10/06 09:00
PMCR- 2004/02/01
CRDT- 2004/02/18 05:00
PHST- 2004/02/18 05:00 [pubmed]
PHST- 2004/10/06 09:00 [medline]
PHST- 2004/02/18 05:00 [entrez]
PHST- 2004/02/01 00:00 [pmc-release]
AID - 200402113 [pii]
AID - 10.3346/jkms.2004.19.1.113 [doi]
PST - ppublish
SO  - J Korean Med Sci. 2004 Feb;19(1):113-22. doi: 10.3346/jkms.2004.19.1.113.